Pharma major Cipla's first quarter net profit surged 58% year-on-year to Rs 401 crore. The margin improvement was extremely healthy at around 27.6%. Pharma major Cipla's first quarter net profit surged 58% year-on-year to Rs 401 crore. The margin improvement was extremely healthy at around 27.6%.

Cipla Q1 PAT seen up 21% to Rs 306 cr

Drug producer Cipla is set to declare its results for the quarter ended June 2012. Analysts on an average expect the profit after tax to grow by 21% year-on-year and 5% quarter-on-quarter to Rs 306 crore in the quarter.

Adj PAT of healthcare sector likely to grow 11% YoY: MOSt

Motilal Oswal expects topline growth of 22% YoY for their Healthcare universe (excluding one-offs), with robust EBITDA growth of 35% YoY. Adjusted PAT is likely to grow 11% YoY, says Motilal Oswal.

Cipla Q4 PAT likely to jump 38% to Rs 295 cr

Pharmaceutical company Cipla is expected to report a growth of 38% year-on-year and 9.4% quarter-on-quarter in its profit after tax of Rs 295 crore for the fourth quarter of FY12, according to CNBC-TV18 poll.

Cipla Q3 PAT likely to grow 32% at Rs 307 cr

India's second largest pharma company by market cap Cipla is likely to report a profit after tax of Rs 307 crore in the October-December quarter of FY12, a massive growth of 32% as compared to Rs 232.7 crore in a year ago quarter.

Looking to increase exports for price advantage: Cipla

Chairman and managing director of Cipla, YK Hamied, tells CNBC-TV18 that they intend to increase the ratio of exports to total sales so as to avail the benefit of higher international prices.

Cipla Sept qtr PAT seen up 13% at Rs 297cr: Angel

Angel Broking has come out with its earning estimates on pharma sector for the quarter ended September 2011. According to the research firm, Cipla September quarter net sales are expected to go up by 8.9% at Rs 1,742 crore, year-on-year, (YoY) basis.

Apr-June qtr: Pharma cos to see healthy sales, sick margins

Pharmaceutical sector has been in the pink of health this year with most stocks outperforming the broader market since the beginning of April. However, there could be some suffering ahead.

Cipla Jun qtr PAT seen down 5% at Rs 245 cr

PINC Research has come out with its earning estimates on pharma sector for the quarter ended June 2011. According to the research firm, Cipla's June quarter net revenues are expected to go up by 12.7% at Rs 1667.2 crore, year-on-year, (YoY) basis.

Cipla disappoints; says Indore SEZ to add 10% to FY12 sales

Rationalising the company's dismal performance during the quarter, chairman and managing director YK Hamied said that the special economic zone (SEZ) at Indore and higher material costs led to lower profitability. "Also, selling anti AIDS and malaria drugs to Africa at humanitarian prices too had an impact."

Cipla Q4 PAT seen down 12% to Rs 243 cr

Cipla is to announce its fourth quarter results. According to CNBC-TV18’s estimates, the company’s Q4FY11 revenues are seen up 11.2% to Rs 1528 crore versus Rs 1375 crore.

Cipla Mar qtr PAT seen down at Rs 206.5 cr: MOST

Motilal Oswal has come out with its earning estimates on Pharmaceuticals sector for the quarter ended March 2011. According to the research firm, Cipla March quarter sales are expected to go up by 10.2% at Rs 1488 crore, year-on-year, (YoY) basis.

Dynamics of domestic market are changing: Cipla

In an interview with CNBC-TV18, S Radhakrishnan, Wholetime Director, Cipla, speaks about the results and gives his outlook going forward.

Cipla Q3 profit after tax seen down 7% at Rs 269 cr

Indian drug maker Cipla is set to report profit after tax of Rs 269 crore for the quarter ended December 2010, down 7% as compared to Rs 289 crore in same quarter the previous year, according to CNBC-TV18 estimates.

Cipla Dec qtr PAT seen down 9.5% at Rs 261.1cr: Angel

Angel Broking has come out with its earning estimates on the pharmaceutical sector for the quarter ended December 2010. According to the research firm, Cipla December quarter net sales are expected to go up by 15.4% to Rs 1552 crore, Year-on-Year, (Y-o-Y) basis.

Cipla Dec qtr PAT seen down 6.9% at Rs 287.5cr: Emkay

Emkay Global Financial Services has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Cipla December quarter sales are expected to go up by 11.8% to Rs 1607.5 crore, Year-on-Year, (Y-o-Y) basis.